FDA Approves Daratumumab Plus Hyaluronidase-Fihj, Carfilzomib, and Dexamethasone for Multiple Myeloma

The FDA has approved daratumumab plus hyaluronidase-fihj (Darlazex Faspro®, Janssen Biotech) in combination with carfilzomib (Kyprolis®, Amgen) plus dexamethasone for patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior lines of therapy. "Daratumumab is a human immunoglobulin G kappa monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action," wrote Ajai Chari, MD, Professor of Medicine, Hematology, and Medical Oncology at ...

Continue reading

Treating Triple-Class Refractory Myeloma With Ajai Chari, MD

​With increasing frequency, multiple myeloma is becoming triple-class refractory, or refractory to all three primary classes of drugs used in its treatment. What is to be done in such cases? In the phase 2b STORM study, now published in The New England Journal of Medicine, Ajai Chari, MD, and colleagues report that a combination of oral selinexor and dexamethasone shows efficacy in patients with triple-class refractory disease. In this interview with i3 Health, Dr. Chari discusses the importance...

Continue reading

Selinexor/Dexamethasone for Triple-Class Refractory Myeloma

A combination of oral selinexor and dexamethasone shows objective responses in patients with multiple myeloma that is refractory to three different classes of currently available therapies, report the investigators of the phase 2b STORM study. ''An increasing number of patients have triple-class refractory myeloma, defined as disease refractory to proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies," write the researchers in their publication in The New England Journal of M...

Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.